Results from Mendelian randomisation analysis on the associations between genetically proxied inhibition of drug targets, reduction of LDLR levels of LDL-c levels, and the levels of testosterone.

Summary of estimated genetic additive effects of rs4238001 allele T on LDL-C (mg/dL), LDL particle number (nmol/L) and LDL particle size (log nm) under a basic regression model (Model 1).

Ani Manichaikul (110134)
Xin-Qun Wang (713819)
Solomon K. Musani (223808)
David M. Herrington (566215)
Wendy S. Post (228765)
James G. Wilson (113688)
Stephen S. Rich (110262)
Annabelle Rodriguez (742007)

May 2015

<p>Analyses were conducted stratified by race/ethnic group and combined by meta-analysis, for all pa...

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9.

Schmidt, A.F.
Holmes, M.V.
Preiss, D.
Swerdlow, D.I.
Denaxas, S.
Fatemifar, G.
Faraway, R.
Finan, C.
Valentine, D.
Fairhurst-Hunter, Z.
Hartwig, F.P.
Horta, B.L.
Hypponen, E.
Power, C.
Moldovan, M.
van Iperen, E.
Hovingh, K.
Demuth, I.
Norman, K.
Steinhagen-Thiessen, E.
Demuth, J.
Bertram, L.
Lill, C.M.
Coassin, S.
Willeit, J.
Kiechl, S.
Willeit, K.
Mason, D.
Wright, J.
Morris, R.
Wanamethee, G.
Whincup, P.
Ben-Shlomo, Y.
McLachlan, S.
Price, J.F.
Kivimaki, M.
Welch, C.
Sanchez-Galvez, A.
Marques-Vidal, P.
Nicolaides, A.
Panayiotou, A.G.
Onland-Moret, N.C.
van der Schouw, Y.T.
Matullo, G.
Fiorito, G.
Guarrera, S.
Sacerdote, C.
Wareham, N.J.
Langenberg, C.
Scott, R.A.
Luan, J.
Bobak, M.
Malyutina, S.
Pająk, A.
Kubinova, R.
Tamosiunas, A.
Pikhart, H.
Grarup, N.
Pedersen, O.
Hansen, T.
Linneberg, A.
Jess, T.
Cooper, J.
Humphries, S.E.
Brilliant, M.
Kitchner, T.
Hakonarson, H.
Carrell, D.S.
McCarty, C.A.
Lester, K.H.
Larson, E.B.
Crosslin, D.R.
de Andrade, M.
Roden, D.M.
Denny, J.C.
Carty, C.
Hancock, S.
Attia, J.
Holliday, E.
Scott, R.
Schofield, P.
O'Donnell, M.
Yusuf, S.
Chong, M.
Pare, G.
van der Harst, P.
Said, M.A.
Eppinga, R.N.
Verweij, N.
Snieder, H.
Christen, T.
Mook-Kanamori, D.O.
Gustafsson, S.
Lind, L.
Ingelsson, E.
Pazoki, R.
Franco, O.
Hofman, A.
Uitterlinden, A.
Dehghan, A.
Teumer, A.
Baumeister, S.
Dörr, M.
Lerch, M.M.
Völker, U.
Völzke, H.
Ward, J.
Pell, J.P.
Meade, T.
Christophersen, I.E.
Maitland-van der Zee, A.H.
Baranova, E.V.
Young, R.
Ford, I.
Campbell, A.
Padmanabhan, S.
Bots, M.L.
Grobbee, D.E.
Froguel, P.
Thuillier, D.
Roussel, R.
Bonnefond, A.
Cariou, B.
Smart, M.
Bao, Y.
Kumari, M.
Mahajan, A.
Hopewell, J.C.
Seshadri, S.
Dale, C.
Costa, RPE
Ridker, P.M.
Chasman, D.I.
Reiner, A.P.
Ritchie, M.D.
Lange, L.A.
Cornish, A.J.
Dobbins, S.E.
Hemminki, K.
Kinnersley, B.
Sanson, M.
Labreche, K.
Simon, M.
Bondy, M.
Law, P.
Speedy, H.
Allan, J.
Li, N.
Went, M.
Weinhold, N.
Morgan, G.
Sonneveld, P.
Nilsson, B.
Goldschmidt, H.
Sud, A.
Engert, A.
Hansson, M.
Hemingway, H.
Asselbergs, F.W.
Patel, R.S.
Keating, B.J.
Sattar, N.
Houlston, R.
Casas, J.P.
Hingorani, A.D.

October 2019

We characterised the phenotypic consequence of genetic variation at the PCSK9 locus and compared fin...

Table_1_Genetic association of lipid-lowering drug target genes with erectile dysfunction and male reproductive health.docx

Quanxin Su (11108780)
Rui Wang (52434)
Yayin Luo (17661456)
Qizhen Tang (13044634)
Kenan Wang (11136195)

February 2024

ObjectiveThe effect of hypolipidemic drugs on male erectile function is still controversial. This Me...

Results from Mendelian randomisation analysis on the associations between genetically proxied inhibition of drug targets, reduction of LDLR levels of LDL-c levels, and body mass index.

Si Fang (14321990)
James Yarmolinsky (739630)
Dipender Gill (5514923)
Caroline J. Bull (8654428)
Claire M. Perks (14321993)
George Davey Smith (7180727)
Tom R. Gaunt (7747922)
Tom G. Richardson (7779047)

January 2023

Estimates are effects equivalent to 1 SD reduction in LDL-c levels or 1 SD reduction in plasma prote...

Results from Mendelian randomisation analysis on the associations between genetically proxied inhibition of drug targets, reduction of LDLR levels of LDL-c levels, and the levels of lipoprotein A.

Si Fang (14321990)
James Yarmolinsky (739630)
Dipender Gill (5514923)
Caroline J. Bull (8654428)
Claire M. Perks (14321993)
George Davey Smith (7180727)
Tom R. Gaunt (7747922)
Tom G. Richardson (7779047)

January 2023

Estimates are effects equivalent to 1 SD reduction in LDL-c levels or 1 SD reduction in plasma prote...

Results from drug target MR analyses to investigate the effect of lipid-lowering therapies on BMI, lipoprotein A, and testosterone.

Si Fang (14321990)
James Yarmolinsky (739630)
Dipender Gill (5514923)
Caroline J. Bull (8654428)
Claire M. Perks (14321993)
George Davey Smith (7180727)
Tom R. Gaunt (7747922)
Tom G. Richardson (7779047)

January 2023

Estimates of effects from genetically proxied inhibition of PCSK9, NPC1L1, and HMGCR on BMI, levels ...

Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study.

Si Fang
James Yarmolinsky
Dipender Gill
Caroline J Bull
Claire M Perks
PRACTICAL Consortium
George Davey Smith
Tom R Gaunt
Tom G Richardson

January 2023

BackgroundProstate cancer (PrCa) is the second most prevalent malignancy in men worldwide. Observati...

Study overview.

Si Fang (14321990)
James Yarmolinsky (739630)
Dipender Gill (5514923)
Caroline J. Bull (8654428)
Claire M. Perks (14321993)
George Davey Smith (7180727)
Tom R. Gaunt (7747922)
Tom G. Richardson (7779047)

January 2023

aThe LDL-c variants were oriented to be in the LDL-c lowering direction, i.e., effect estimates in M...

Results from MR analyses to estimate the effect of lipid-lowering therapies and risk factors on overall prostate cancer risk.

Si Fang (14321990)
James Yarmolinsky (739630)
Dipender Gill (5514923)
Caroline J. Bull (8654428)
Claire M. Perks (14321993)
George Davey Smith (7180727)
Tom R. Gaunt (7747922)
Tom G. Richardson (7779047)

January 2023

Effect estimates are odds ratios for prostate cancer per 1 SD reduction in LDL-c proxied using genet...

Association between genetically proxied PCSK9 inhibition and prostate cancer risk:A Mendelian randomisation study

January 2023

BackgroundProstate cancer (PrCa) is the second most prevalent malignancy in men worldwide. Observati...

The evolution of mendelian randomization for investigating drug effects

Gill, Dipender
Burgess, Stephen

February 2022

Dipender Gill and Stephen Burgess discuss the accompanying study by James Yarmolinsky and colleagues...

The evolution of mendelian randomization for investigating drug effects.

Gill, Dipender
Burgess, Stephen

March 2022

Dipender Gill and Stephen Burgess discuss the accompanying study by James Yarmolinsky and colleagues...

Mendelian randomization analysis of individual SNPS (with cholesterol in small LDL as the outcome).

Fengyi Zhang (805423)
Yufeng Zhang (195768)
Jiayi Zhang (5470265)
Xin Wang (91924)
Yujie Li (294983)
Wenbo Wang (300277)

February 2024

Mendelian randomization analysis of individual SNPS (with cholesterol in small LDL as the outcome).<...

Results from sensitivity tests on the PCSK9 drug target Mendelian randomisation on total prostate cancer risk.

Si Fang (14321990)
James Yarmolinsky (739630)
Dipender Gill (5514923)
Caroline J. Bull (8654428)
Claire M. Perks (14321993)
George Davey Smith (7180727)
Tom R. Gaunt (7747922)
Tom G. Richardson (7779047)

January 2023

These analyses were performed using genetic instruments identified from the Global Lipids Genetics C...

Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents

Troutt Jason S
Konrad Robert J
Cao Guoqing

February 2011

Abstract Background During the past decade, proprotein convertase subtilisin kexin type 9 (PCSK9) ha...

Summary of estimated genetic additive effects of rs4238001 allele T on LDL-C (mg/dL), LDL particle number (nmol/L) and LDL particle size (log nm) under a basic regression model (Model 1).

Ani Manichaikul (110134)
Xin-Qun Wang (713819)
Solomon K. Musani (223808)
David M. Herrington (566215)
Wendy S. Post (228765)
James G. Wilson (113688)
Stephen S. Rich (110262)
Annabelle Rodriguez (742007)

May 2015

<p>Analyses were conducted stratified by race/ethnic group and combined by meta-analysis, for all pa...

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9.

Schmidt, A.F.
Holmes, M.V.
Preiss, D.
Swerdlow, D.I.
Denaxas, S.
Fatemifar, G.
Faraway, R.
Finan, C.
Valentine, D.
Fairhurst-Hunter, Z.
Hartwig, F.P.
Horta, B.L.
Hypponen, E.
Power, C.
Moldovan, M.
van Iperen, E.
Hovingh, K.
Demuth, I.
Norman, K.
Steinhagen-Thiessen, E.
Demuth, J.
Bertram, L.
Lill, C.M.
Coassin, S.
Willeit, J.
Kiechl, S.
Willeit, K.
Mason, D.
Wright, J.
Morris, R.
Wanamethee, G.
Whincup, P.
Ben-Shlomo, Y.
McLachlan, S.
Price, J.F.
Kivimaki, M.
Welch, C.
Sanchez-Galvez, A.
Marques-Vidal, P.
Nicolaides, A.
Panayiotou, A.G.
Onland-Moret, N.C.
van der Schouw, Y.T.
Matullo, G.
Fiorito, G.
Guarrera, S.
Sacerdote, C.
Wareham, N.J.
Langenberg, C.
Scott, R.A.
Luan, J.
Bobak, M.
Malyutina, S.
Pająk, A.
Kubinova, R.
Tamosiunas, A.
Pikhart, H.
Grarup, N.
Pedersen, O.
Hansen, T.
Linneberg, A.
Jess, T.
Cooper, J.
Humphries, S.E.
Brilliant, M.
Kitchner, T.
Hakonarson, H.
Carrell, D.S.
McCarty, C.A.
Lester, K.H.
Larson, E.B.
Crosslin, D.R.
de Andrade, M.
Roden, D.M.
Denny, J.C.
Carty, C.
Hancock, S.
Attia, J.
Holliday, E.
Scott, R.
Schofield, P.
O'Donnell, M.
Yusuf, S.
Chong, M.
Pare, G.
van der Harst, P.
Said, M.A.
Eppinga, R.N.
Verweij, N.
Snieder, H.
Christen, T.
Mook-Kanamori, D.O.
Gustafsson, S.
Lind, L.
Ingelsson, E.
Pazoki, R.
Franco, O.
Hofman, A.
Uitterlinden, A.
Dehghan, A.
Teumer, A.
Baumeister, S.
Dörr, M.
Lerch, M.M.
Völker, U.
Völzke, H.
Ward, J.
Pell, J.P.
Meade, T.
Christophersen, I.E.
Maitland-van der Zee, A.H.
Baranova, E.V.
Young, R.
Ford, I.
Campbell, A.
Padmanabhan, S.
Bots, M.L.
Grobbee, D.E.
Froguel, P.
Thuillier, D.
Roussel, R.
Bonnefond, A.
Cariou, B.
Smart, M.
Bao, Y.
Kumari, M.
Mahajan, A.
Hopewell, J.C.
Seshadri, S.
Dale, C.
Costa, RPE
Ridker, P.M.
Chasman, D.I.
Reiner, A.P.
Ritchie, M.D.
Lange, L.A.
Cornish, A.J.
Dobbins, S.E.
Hemminki, K.
Kinnersley, B.
Sanson, M.
Labreche, K.
Simon, M.
Bondy, M.
Law, P.
Speedy, H.
Allan, J.
Li, N.
Went, M.
Weinhold, N.
Morgan, G.
Sonneveld, P.
Nilsson, B.
Goldschmidt, H.
Sud, A.
Engert, A.
Hansson, M.
Hemingway, H.
Asselbergs, F.W.
Patel, R.S.
Keating, B.J.
Sattar, N.
Houlston, R.
Casas, J.P.
Hingorani, A.D.

October 2019

We characterised the phenotypic consequence of genetic variation at the PCSK9 locus and compared fin...

Table_1_Genetic association of lipid-lowering drug target genes with erectile dysfunction and male reproductive health.docx

Quanxin Su (11108780)
Rui Wang (52434)
Yayin Luo (17661456)
Qizhen Tang (13044634)
Kenan Wang (11136195)

February 2024

ObjectiveThe effect of hypolipidemic drugs on male erectile function is still controversial. This Me...

Results from Mendelian randomisation analysis on the associations between genetically proxied inhibition of drug targets, reduction of LDLR levels of LDL-c levels, and body mass index.

Si Fang (14321990)
James Yarmolinsky (739630)
Dipender Gill (5514923)
Caroline J. Bull (8654428)
Claire M. Perks (14321993)
George Davey Smith (7180727)
Tom R. Gaunt (7747922)
Tom G. Richardson (7779047)

January 2023

Estimates are effects equivalent to 1 SD reduction in LDL-c levels or 1 SD reduction in plasma prote...

Results from Mendelian randomisation analysis on the associations between genetically proxied inhibition of drug targets, reduction of LDLR levels of LDL-c levels, and the levels of lipoprotein A.

Si Fang (14321990)
James Yarmolinsky (739630)
Dipender Gill (5514923)
Caroline J. Bull (8654428)
Claire M. Perks (14321993)
George Davey Smith (7180727)
Tom R. Gaunt (7747922)
Tom G. Richardson (7779047)

January 2023

Estimates are effects equivalent to 1 SD reduction in LDL-c levels or 1 SD reduction in plasma prote...

Results from drug target MR analyses to investigate the effect of lipid-lowering therapies on BMI, lipoprotein A, and testosterone.

Si Fang (14321990)
James Yarmolinsky (739630)
Dipender Gill (5514923)
Caroline J. Bull (8654428)
Claire M. Perks (14321993)
George Davey Smith (7180727)
Tom R. Gaunt (7747922)
Tom G. Richardson (7779047)

January 2023

Estimates of effects from genetically proxied inhibition of PCSK9, NPC1L1, and HMGCR on BMI, levels ...

Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study.

Si Fang
James Yarmolinsky
Dipender Gill
Caroline J Bull
Claire M Perks
PRACTICAL Consortium
George Davey Smith
Tom R Gaunt
Tom G Richardson

January 2023

BackgroundProstate cancer (PrCa) is the second most prevalent malignancy in men worldwide. Observati...

Study overview.

Si Fang (14321990)
James Yarmolinsky (739630)
Dipender Gill (5514923)
Caroline J. Bull (8654428)
Claire M. Perks (14321993)
George Davey Smith (7180727)
Tom R. Gaunt (7747922)
Tom G. Richardson (7779047)

January 2023

aThe LDL-c variants were oriented to be in the LDL-c lowering direction, i.e., effect estimates in M...

Results from MR analyses to estimate the effect of lipid-lowering therapies and risk factors on overall prostate cancer risk.

Si Fang (14321990)
James Yarmolinsky (739630)
Dipender Gill (5514923)
Caroline J. Bull (8654428)
Claire M. Perks (14321993)
George Davey Smith (7180727)
Tom R. Gaunt (7747922)
Tom G. Richardson (7779047)

January 2023

Effect estimates are odds ratios for prostate cancer per 1 SD reduction in LDL-c proxied using genet...

Association between genetically proxied PCSK9 inhibition and prostate cancer risk:A Mendelian randomisation study

January 2023

BackgroundProstate cancer (PrCa) is the second most prevalent malignancy in men worldwide. Observati...

The evolution of mendelian randomization for investigating drug effects

Gill, Dipender
Burgess, Stephen

February 2022

Dipender Gill and Stephen Burgess discuss the accompanying study by James Yarmolinsky and colleagues...

The evolution of mendelian randomization for investigating drug effects.

Gill, Dipender
Burgess, Stephen

March 2022

Dipender Gill and Stephen Burgess discuss the accompanying study by James Yarmolinsky and colleagues...

Mendelian randomization analysis of individual SNPS (with cholesterol in small LDL as the outcome).

Fengyi Zhang (805423)
Yufeng Zhang (195768)
Jiayi Zhang (5470265)
Xin Wang (91924)
Yujie Li (294983)
Wenbo Wang (300277)

February 2024

Mendelian randomization analysis of individual SNPS (with cholesterol in small LDL as the outcome).<...

Results from sensitivity tests on the PCSK9 drug target Mendelian randomisation on total prostate cancer risk.

Si Fang (14321990)
James Yarmolinsky (739630)
Dipender Gill (5514923)
Caroline J. Bull (8654428)
Claire M. Perks (14321993)
George Davey Smith (7180727)
Tom R. Gaunt (7747922)
Tom G. Richardson (7779047)

January 2023

These analyses were performed using genetic instruments identified from the Global Lipids Genetics C...

Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents

Troutt Jason S
Konrad Robert J
Cao Guoqing

February 2011

Abstract Background During the past decade, proprotein convertase subtilisin kexin type 9 (PCSK9) ha...

Summary of estimated genetic additive effects of rs4238001 allele T on LDL-C (mg/dL), LDL particle number (nmol/L) and LDL particle size (log nm) under a basic regression model (Model 1).

Ani Manichaikul (110134)
Xin-Qun Wang (713819)
Solomon K. Musani (223808)
David M. Herrington (566215)
Wendy S. Post (228765)
James G. Wilson (113688)
Stephen S. Rich (110262)
Annabelle Rodriguez (742007)

May 2015

<p>Analyses were conducted stratified by race/ethnic group and combined by meta-analysis, for all pa...

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9.

Schmidt, A.F.
Holmes, M.V.
Preiss, D.
Swerdlow, D.I.
Denaxas, S.
Fatemifar, G.
Faraway, R.
Finan, C.
Valentine, D.
Fairhurst-Hunter, Z.
Hartwig, F.P.
Horta, B.L.
Hypponen, E.
Power, C.
Moldovan, M.
van Iperen, E.
Hovingh, K.
Demuth, I.
Norman, K.
Steinhagen-Thiessen, E.
Demuth, J.
Bertram, L.
Lill, C.M.
Coassin, S.
Willeit, J.
Kiechl, S.
Willeit, K.
Mason, D.
Wright, J.
Morris, R.
Wanamethee, G.
Whincup, P.
Ben-Shlomo, Y.
McLachlan, S.
Price, J.F.
Kivimaki, M.
Welch, C.
Sanchez-Galvez, A.
Marques-Vidal, P.
Nicolaides, A.
Panayiotou, A.G.
Onland-Moret, N.C.
van der Schouw, Y.T.
Matullo, G.
Fiorito, G.
Guarrera, S.
Sacerdote, C.
Wareham, N.J.
Langenberg, C.
Scott, R.A.
Luan, J.
Bobak, M.
Malyutina, S.
Pająk, A.
Kubinova, R.
Tamosiunas, A.
Pikhart, H.
Grarup, N.
Pedersen, O.
Hansen, T.
Linneberg, A.
Jess, T.
Cooper, J.
Humphries, S.E.
Brilliant, M.
Kitchner, T.
Hakonarson, H.
Carrell, D.S.
McCarty, C.A.
Lester, K.H.
Larson, E.B.
Crosslin, D.R.
de Andrade, M.
Roden, D.M.
Denny, J.C.
Carty, C.
Hancock, S.
Attia, J.
Holliday, E.
Scott, R.
Schofield, P.
O'Donnell, M.
Yusuf, S.
Chong, M.
Pare, G.
van der Harst, P.
Said, M.A.
Eppinga, R.N.
Verweij, N.
Snieder, H.
Christen, T.
Mook-Kanamori, D.O.
Gustafsson, S.
Lind, L.
Ingelsson, E.
Pazoki, R.
Franco, O.
Hofman, A.
Uitterlinden, A.
Dehghan, A.
Teumer, A.
Baumeister, S.
Dörr, M.
Lerch, M.M.
Völker, U.
Völzke, H.
Ward, J.
Pell, J.P.
Meade, T.
Christophersen, I.E.
Maitland-van der Zee, A.H.
Baranova, E.V.
Young, R.
Ford, I.
Campbell, A.
Padmanabhan, S.
Bots, M.L.
Grobbee, D.E.
Froguel, P.
Thuillier, D.
Roussel, R.
Bonnefond, A.
Cariou, B.
Smart, M.
Bao, Y.
Kumari, M.
Mahajan, A.
Hopewell, J.C.
Seshadri, S.
Dale, C.
Costa, RPE
Ridker, P.M.
Chasman, D.I.
Reiner, A.P.
Ritchie, M.D.
Lange, L.A.
Cornish, A.J.
Dobbins, S.E.
Hemminki, K.
Kinnersley, B.
Sanson, M.
Labreche, K.
Simon, M.
Bondy, M.
Law, P.
Speedy, H.
Allan, J.
Li, N.
Went, M.
Weinhold, N.
Morgan, G.
Sonneveld, P.
Nilsson, B.
Goldschmidt, H.
Sud, A.
Engert, A.
Hansson, M.
Hemingway, H.
Asselbergs, F.W.
Patel, R.S.
Keating, B.J.
Sattar, N.
Houlston, R.
Casas, J.P.
Hingorani, A.D.

October 2019

We characterised the phenotypic consequence of genetic variation at the PCSK9 locus and compared fin...

Table_1_Genetic association of lipid-lowering drug target genes with erectile dysfunction and male reproductive health.docx

Quanxin Su (11108780)
Rui Wang (52434)
Yayin Luo (17661456)
Qizhen Tang (13044634)
Kenan Wang (11136195)

February 2024

ObjectiveThe effect of hypolipidemic drugs on male erectile function is still controversial. This Me...

Results from Mendelian randomisation analysis on the associations between genetically proxied inhibition of drug targets, reduction of LDLR levels of LDL-c levels, and the levels of testosterone.

Abstract

Extracted data

Results from Mendelian randomisation analysis on the associations between genetically proxied inhibition of drug targets, reduction of LDLR levels of LDL-c levels, and the levels of testosterone.

Abstract

Extracted data

Related items

Related items